Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

KZR - Kezar Life Sciences Inc Stock Price, Fair Value and News

$5.79-0.04 (-0.69%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

KZR Price Action

Last 30 days

-3.6%

Last 90 days

-13.6%

Trailing 12 Months

-37.0%

KZR RSI Chart

JunJulAugSepOctNovDec2025FebMar102030405060708090

KZR Valuation

Market Cap

42.8M

Price/Earnings (Trailing)

-0.45

Price/Sales (Trailing)

7.81

Price/Free Cashflow

-0.56

KZR Price/Sales (Trailing)

2024AprJulOct67891011

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KZR Fundamentals

KZR Revenue

Revenue (TTM)

7.0M

Oct2024AprJul7M

KZR Earnings

Earnings (TTM)

-95.8M

Earnings Growth (Yr)

12.08%

Earnings Growth (Qtr)

5.73%

2018202020222024-100M-80M-60M-40M-20M0

KZR Profitability

Return on Equity

-71.45%

Return on Assets

-58.37%

Free Cashflow Yield

-178.66%

KZR Investor Care

Shares Dilution (1Y)

0.37%

Diluted EPS (TTM)

-13.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Dec7M
Net sales
YearQ1Q2Q3Q4
20240000
20230007.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Kezar Life Sciences Inc

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEkezarlifesciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES84

Kezar Life Sciences Inc Frequently Asked Questions

What is the ticker symbol for Kezar Life Sciences Inc? What does KZR stand for in stocks?

KZR is the stock ticker symbol of Kezar Life Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kezar Life Sciences Inc (KZR)?

As of Wed Mar 12 2025, market cap of Kezar Life Sciences Inc is 42.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KZR stock?

You can check KZR's fair value in chart for subscribers.

Is Kezar Life Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether KZR is over valued or under valued. Whether Kezar Life Sciences Inc is cheap or expensive depends on the assumptions which impact Kezar Life Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KZR.

What is Kezar Life Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 12 2025, KZR's PE ratio (Price to Earnings) is -0.45 and Price to Sales (PS) ratio is 7.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KZR PE ratio will change depending on the future growth rate expectations of investors.